title: B-cell activating factor (BAFF) promotes CpG ODN-induced B cell activation and proliferation.
abstract: It is controversial whether naïve B cells are directly activated in response to TLR9 ligand, CpG ODN. Although bovine blood-derived CD21(+) B cells express TLR9 and proliferate in response to CpG in mixed-cell populations, purified bovine B cells do not proliferate significantly in response to CpG ODN, even when the B cell receptor is engaged. When co-cultured with CD14(+) myeloid cells and/or B-cell activating factor (BAFF), a cytokine produced by activated myeloid cells, there was a significant increase in CpG-specific B cell proliferation, and the number of large B cells in general or positive for CD25, all of which are markers for B cell activation. These data suggest that activated myeloid cells and BAFF prime B cells for significant CpG-specific activation. Understanding the signals required to mediate efficient CpG-induced, antigen-independent and T-cell independent activation of B cells has implications for polyclonal B cell activation and the development of autoimmune diseases.
authors: Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatchewan, Canada.
authors: Rachelle M
authors: RM
authors: Buchanan
authors: Yurij
authors: Y
authors: Popowych
authors: Natasha
authors: N
authors: Arsic
authors: Hugh G G
authors: HG
authors: Townsend
authors: George K
authors: GK
authors: Mutwiri
authors: Andrew A
authors: AA
authors: Potter
authors: Lorne A
authors: LA
authors: Babiuk
authors: Philip J
authors: PJ
authors: Griebel
authors: Heather L
authors: HL
authors: Wilson
mesh_terms: D000818:Animals; D053264:B-Cell Activating Factor / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D002417:Cattle; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D018920:Coculture Techniques; D004357:Drug Synergism; D005434:Flow Cytometry; D057809:HEK293 Cells; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D018950:Lipopolysaccharide Receptors / Q000276:immunology / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects* / Q000276:immunology; D008297:Male; D022423:Myeloid Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D011947:Receptors, Antigen, B-Cell / Q000276:immunology / Q000378:metabolism; D017464:Receptors, Complement 3d / Q000276:immunology / Q000378:metabolism; D011994:Recombinant Proteins / Q000276:immunology / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D051217:Toll-Like Receptor 9 / Q000235:genetics / Q000276:immunology / Q000378:metabolism
chemical_list: D053264:B-Cell Activating Factor; C408982:CPG-oligonucleotide; D018950:Lipopolysaccharide Receptors; D009838:Oligodeoxyribonucleotides; D011947:Receptors, Antigen, B-Cell; D017464:Receptors, Complement 3d; D011994:Recombinant Proteins; D051217:Toll-Like Receptor 9